Abstract | BACKGROUND: OBJECTIVE: METHODS: In this prospective study, we measured autoantibody titres to both BP Ag1 and BP Ag2, in 10 patients with severe BP, over a period of 18 consecutive months on each patient, using an immunoblot assay. RESULTS: Prior to the initiation of IVIg therapy, the sera of nine patients demonstrated the presence of high autoantibody titres to both BP Ag1 and BP Ag2. One patient had autoantibodies to BP Ag1 only. A statistically significant decline in the autoantibody titres to both BP Ag1 and BP Ag2 was observed after 3 months of receiving the first cycle of IVIg therapy. This gradual decline in autoantibody titres continued until patients were observed to have non-detectable titres to BP Ag1 after 11 months and to BP Ag2 after 10 months of receiving IVIg therapy. Once patients achieved non-detectable titres, these patients were considered to be in a serological remission. This serological remission was sustained for an additional 7 months of observation. CONCLUSION:
Autoantibody titres to BP Ag1 and BP Ag2 can be used to monitor the serological response to treatment in patients with BP. Patients with severe BP who are treated with IVIg therapy, as described in our protocol, achieve a long-term serological remission.
|
Authors | N Sami, S Ali, K C Bhol, A R Ahmed |
Journal | Journal of the European Academy of Dermatology and Venereology : JEADV
(J Eur Acad Dermatol Venereol)
Vol. 17
Issue 6
Pg. 641-5
(Nov 2003)
ISSN: 0926-9959 [Print] England |
PMID | 14761129
(Publication Type: Comparative Study, Journal Article)
|
Chemical References |
- Autoantibodies
- Autoantigens
- Carrier Proteins
- Cytoskeletal Proteins
- DST protein, human
- Dystonin
- Immunoglobulins, Intravenous
- Nerve Tissue Proteins
- Non-Fibrillar Collagens
- Collagen
|
Topics |
- Aged
- Aged, 80 and over
- Analysis of Variance
- Autoantibodies
(drug effects, immunology)
- Autoantigens
(analysis, immunology)
- Carrier Proteins
- Case-Control Studies
- Collagen
(analysis, immunology)
- Cytoskeletal Proteins
- Dose-Response Relationship, Drug
- Drug Administration Schedule
- Dystonin
- Enzyme-Linked Immunosorbent Assay
- Female
- Follow-Up Studies
- Humans
- Immunization, Passive
(methods)
- Immunoblotting
- Immunoglobulins, Intravenous
(administration & dosage)
- Male
- Nerve Tissue Proteins
- Non-Fibrillar Collagens
- Pemphigoid, Bullous
(immunology, therapy)
- Prospective Studies
- Reference Values
- Risk Assessment
- Severity of Illness Index
- Treatment Outcome
- Collagen Type XVII
|